Active Not Recruiting
OBSERVATIONAL
NCT06485089
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.
Detailed Description
Women who are scheduled to take tirzepatide for weight loss will be assessed before and after taking drug for change in risk biomarkers. These include mammography, DXA scan, blood draw, and random periareolar fine needle aspiration (RPFNA) for acquisition of benign breast tissue.
Interventions
Name:
tirzepatide
Type:
DRUG
Description:
Women taking tirzepatide as part of standard care in the Weight Managment Clinic
Primary Outcomes
Measure:
Feasibility of design as assessed by accrual rate of 1 or more per month over 12 months
TimeFrame:
12 months
Description:
Accrual defined as signed consent and ompleting baseline proceedures
Measure:
Completion rate of 70% or more
TimeFrame:
6 months
Description:
Completion of procedures for biomarker assessment after 3-6 months of tirzeptide
Trial Information
NCT ID
NCT06485089
Status
Active Not Recruiting
Study Type
OBSERVATIONAL
Sponsor
University of Kansas Medical Center
Last Updated
December 15, 2025